Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA Transfected Granulocyte-enriched Cells in CGD
NCT05189925Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2022
- Primary completion
- Jul 2027
- Modality
- mRNA Therapeutics, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CGD-Grans in chronic granulomatous disease (CGD) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Feasibility of CGD-Grans infusion at 3 months, Maximum Tolerated Dose at 3 months and 1 more. Started Jul 2022; status: recruiting.
02
Drugs
CGD-Grans
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT05189925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189925.